PP
COGT icon

Paloma Partners’s Cogent Biosciences COGT Stock Holding History

Paloma Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,390
Closed -$60K – 2195
2019
Q3 		$60K Sell
10,390
-11,285
-52% -$91.7K ﹤0.01% 1868
2019
Q2 		$227K Buy
+21,675
New +$288K ﹤0.01% 1469

Other funds holding COGT

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Paloma Partners's COGT Position: Q4 2019 in Review

Paloma Partners sold out of Cogent Biosciences (COGT) in Q4 2019, closing a stake of 10,390 shares — an estimated $60K sold.

Paloma Partners first reported a position in COGT in Q2 2019 and held it in 2 quarters. The position peaked at $227K in Q2 2019. 27 funds tracked by Wall St. Rank hold COGT as of Q4 2019.

  • Paloma Partners reported no remaining Cogent Biosciences position as of Q4 2019 after selling out during the quarter.
  • Paloma Partners sold 10,390 Cogent Biosciences shares in Q4 2019, an estimated $60K.
  • Paloma Partners first reported a position in Cogent Biosciences in Q2 2019 and held it in 2 quarters.
  • Paloma Partners's Cogent Biosciences position peaked at $227K in Q2 2019.
  • 27 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2019.

Based on Paloma Partners's 13F filing for Q4 2019, filed 14 Feb 2020.